AmorChem partners on project to treat endometriosis and estrogen-linked cancers

AmorChem, an early-stage life sciences fund managed by Canadian venture capital firm GeneChem, has partnered with the Université Laval and CHU de Québec on a project to develop novel drugs for the treatment of endometriosis and estrogen-linked cancers. It was noted that the combined global market for the treatment of breast and endometrial cancers will soon be $15 billion. Québec commercialization hub SOVAR has supported the project's development. AmorChem was this month profiled by peHUB Canada in a feature article about Univalor and new start-up opportunities in Québec.

CanadaNorth AmericaBriefs